Lyophilized ENPP1 Polypeptide Formulations and Uses Thereof

The EPO published patent application EP4404980A1 for BioMarin Pharmaceutical Inc., covering lyophilized ENPP1 polypeptide formulations and uses thereof. The application includes multiple IPC classifications spanning pharmaceutical preparations (A61K), enzyme compositions (C12N), and peptide therapeutics (C07K).

Affected parties include pharmaceutical manufacturers developing enzyme replacement therapies, biotech companies working with ENPP1-related treatments, and healthcare providers administering such therapies. Patent publication establishes intellectual property protection in 37 designated European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.